Use of a super active luteinizing hormone releasing hormone (LHRH) agonist in the treatment of menorrhagia
Authors:
- 1 September 1984
- journal article
- research article
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 91 (9) , 913-916
Abstract
Summary. A luteinizing hormone releasing hormone agonist, d‐Ser(But)6des Gly10‐LHRH ethylamide, was administered intranasally to four women with unexplained ovulatory menorrhagia. Dramatic reductions in excessive menstrual blood losses were induced without significant side‐effects, although the pattern of loss returned to pretreatment levels within 2 months of ceasing therapy.Keywords
This publication has 7 references indexed in Scilit:
- Intranasal treatment with luteinising hormone releasing hormone agonist in women with endometriosis.BMJ, 1983
- FERTILITY AFTER CHILDBIRTH: INFANT FEEDING PATTERNS, BASAL PRL LEVELS AND POST‐PARTUM OVULATIONClinical Endocrinology, 1982
- INTRANASAL LHRH AGONIST TREATMENT FOR INHIBITION OF OVULATION IN WOMEN: CLINICAL ASPECTSClinical Endocrinology, 1982
- Influence of the LH-RH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control?Contraception, 1981
- REDUCTION OF MENSTRUAL BLOOD LOSS BY DANAZOL IN UNEXPLAINED MENORRHAGIA: LACK OF EFFECT OF PLACEBOBJOG: An International Journal of Obstetrics & Gynaecology, 1980
- MORTALITY AMONG WOMEN PARTICIPATING IN THE OXFORD/FAMILY PLANNING ASSOCIATION CONTRACEPTIVE STUDYThe Lancet, 1977
- Determination of Menstrual Blood LossScandinavian Journal of Clinical and Laboratory Investigation, 1964